[3R-(3-ALPHA,6-ALPHA,7A-ALPHA)]-6-METHYL-3-PHENYL-3H,5H-TETRAHYDROPYRROLO-[1,2-C]-OXAZOL-5-ONE
Compound with spectra: 1 NMR, and 1 MS (GC)
![[3R-(3-ALPHA,6-ALPHA,7A-ALPHA)]-6-METHYL-3-PHENYL-3H,5H-TETRAHYDROPYRROLO-[1,2-C]-OXAZOL-5-ONE](/api/compound/8NprYxZU3iB.png?ph=true&h=300&w=458 "[3R-(3-ALPHA,6-ALPHA,7A-ALPHA)]-6-METHYL-3-PHENYL-3H,5H-TETRAHYDROPYRROLO-[1,2-C]-OXAZOL-5-ONE")
| SpectraBase Compound ID | 8NprYxZU3iB |
|---|---|
| InChI | InChI=1S/C13H15NO2/c1-9-7-11-8-16-13(14(11)12(9)15)10-5-3-2-4-6-10/h2-6,9,11,13H,7-8H2,1H3/t9-,11+,13-/m1/s1 |
| InChIKey | ASWGWUAIRIPSBF-SUZMYJTESA-N |
| Mol Weight | 217.27 g/mol |
| Molecular Formula | C13H15NO2 |
| Exact Mass | 217.110279 g/mol |
| Enantiomer InChIKey | ASWGWUAIRIPSBF-NDMJEZRESA-N |
| Copyright | Copyright © 2020-2025 John Wiley & Sons, Inc. All Rights Reserved. |
|---|---|
| Source of Spectrum | D8-329-47-4 |
| Copyright | Copyright © 2016-2025 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
- (3R,6R,7aS)-6-Methyl-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one
- (3R,6.alpha.)-6-Methyl-3-phenyl-3H,5H-tetrahydropyrrolo[1,2-c]oxazol-5-one
- (3R,6R,7aS)-6-methyl-3-phenyltetrahydro-5H-pyrrolo[1,2-c][1,3]oxazol-5-one
- (3R,6R,7aS)-6-methyl-3-phenyl-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-5-one
(5S)-1-Phenylpropyl-5-methoxymethyl-3-ethyl-2-pyrrolidinone
(5S)-1,3-Dibenzyl-5-benzyloxymethyl-2-pyrrolidinone
BBUDODUDKKUFAF-UHFFFAOYSA-N
ZEENTOYQUPDLGW-UHFFFAOYSA-N
KMTZKJAJNNJIIS-UHFFFAOYSA-N
WJUHXGHEMQAODN-UHFFFAOYSA-N
XKXFNHJWJVDUCR-UHFFFAOYSA-N
CJCFJFFPJAZZCF-UHFFFAOYSA-N
IGPKLRBSPAGUDI-UHFFFAOYSA-N
| Title | Journal or Book | Year |
|---|---|---|
| Pyroglutamic Acid in Drug Synthesis, Part 1 A Method for the Synthesis of Enantiomerically Pure 4-Alkyl-4-arylpyroglutamic Acids | Archiv der Pharmazie | 1996 |